Karolinska Development AB Release: Pharma Portfolio Company Announces FDA 510(K) Clearance For Marketing Of OSSDSIGN Cranial For Sale In The U.S.A. - BioLegacy Research

Karolinska Development AB Release: Pharma Portfolio Company Announces FDA 510(K) Clearance For Marketing Of OSSDSIGN Cranial For Sale In The U.S.A.

Post author:Sam
Post published:January 19, 2017
Post category:BioPharma

Life Sciences Jobs …
Source: BioSpace